Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

1.720 +0.020 (+1.18%)
Streaming Delayed Price Updated: 3:56 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adagene Inc. - ADS, each representing 1.25 ordinary shares

< Previous 1 2 3 4 Next >
How Is The Market Feeling About Adagene?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan... 
Via Benzinga
Expert Ratings for Adagene
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Focused Adagene Stock Plummeting Today?
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in... 
Via Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today! 
Via InvestorPlace
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Adagene to Present at Investor and Scientific Conferences in September
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Vericity, Inc. (NASDAQ: VERY) shares climbed 87.4% to $11.12 after iA Financial Group announced it will acquire the company. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updates to its Board of Directors
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
From Adagene Inc.
Via GlobeNewswire
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.